New pill targets Hard-to-Treat cancers in early trial
NCT ID NCT07649200
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests an oral drug called SNH-118110 in 240 adults with advanced solid tumors that have a specific genetic change (RET). The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must have tried other treatments without success.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS WITH RET GENE ALTERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The East Hospital Affiliated to Tongji University, Shanghai
Shanghai, Shanghai Municipality, 200120, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Pronged antibody outsmart advanced solid tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can engineered immune cells target a common ovarian cancer protein?
- Can a new imaging tracer outperform standard scans in finding hidden tumors?
- Spinal injection of dual immunotherapy plus chemotherapy targets cancer spread to brain lining
- Lab-Made immune protein takes on advanced cancers in first human test